文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

芥子气暴露增加COVID-19感染患者死亡风险:一项队列研究

Exposure to sulfur mustard increases the risk for mortality in patients with COVID-19 infection: A cohort study.
PubMed 文献 · Am J Emerg Med · 2021-09-25
一句话结论有芥子气暴露史的COVID-19住院患者28天死亡风险升高(HR 1.92),作者认为应视为高危人群并备好重症监护包括氧疗。

该队列研究于2020年10月至2021年5月纳入960例COVID-19住院患者(192例有芥子气暴露史,768例无暴露),暴露组为男性退伍军人,非暴露组为男性个体年龄匹配者,所有患者RT-PCR及胸部CT均阳性。主要结局为入院28天内死亡。芥子气暴露与COVID-19死亡风险增加相关(HR 1.92,95%CI 1.14–3.24,p=0.013);早期插管提示预后不良(HR 7.34,p<0.001),而较高PaO2(HR 0.97,p<0.001)或入院早期接受氧疗(HR 0.58,p=0.011)者死亡风险较低;哮喘患者死亡风险更高(HR 3.76,p=0.001)。作者认为芥子气暴露的COVID-19患者应视为高危人群,医疗机构应准备提供包括氧疗在内的重症监护。

要点

  • 芥子气暴露的COVID-19住院患者28天死亡风险升高:HR 1.92(95%CI 1.14–3.24),p=0.013。
  • 早期插管提示预后不良:HR 7.34(95%CI 4.65–11.58),p<0.001。
  • 入院早期接受氧疗者死亡风险较低:HR 0.58(95%CI 0.38–0.89),p=0.011。
  • 较高PaO2与较低死亡风险相关:HR 0.97(95%CI 0.95–0.98),p<0.001。
  • 合并哮喘者死亡风险更高:HR 3.76(95%CI 1.69–8.36),p=0.001;暴露组哮喘(p=0.026)及非哮喘肺部疾病(p<0.001)患病率显著更高。

适用人群与场景

  • 2020年10月至2021年5月收治于大学医疗中心的COVID-19住院患者,共960例(192例有芥子气暴露史,768例无暴露)。
  • 暴露组为男性退伍军人,非暴露组为男性个体年龄匹配者。
  • 所有患者COVID-19 RT-PCR检测阳性且胸部CT阳性。

诊断标准与关键阈值

  • COVID-19诊断依据:RT-PCR检测阳性且胸部CT阳性。

处置流程与药物剂量

  • 作者认为,有芥子气暴露史的COVID-19感染者应被视为高危患者,医疗机构应准备为其提供重症监护,包括氧疗。

红旗征与不能漏的情况

  • 早期插管提示预后不良:HR 7.34(95%CI 4.65–11.58),p<0.001。
  • 合并哮喘的COVID-19患者死亡风险更高:HR 3.76(95%CI 1.69–8.36),p=0.001。

研究设计与关键结果

  • 研究类型:队列研究;样本量960例COVID-19住院患者(192例有芥子气暴露史,768例无暴露);暴露组为男性退伍军人,非暴露组为男性个体年龄匹配者。
  • 主要结局为入院28天内死亡;芥子气暴露与COVID-19死亡风险增加相关:HR 1.92(95%CI 1.14–3.24),p=0.013。
  • 早期插管提示预后不良:HR 7.34(95%CI 4.65–11.58),p<0.001。
  • 较高PaO2与较低死亡风险相关:HR 0.97(95%CI 0.95–0.98),p<0.001。
  • 入院早期接受氧疗者死亡风险较低:HR 0.58(95%CI 0.38–0.89),p=0.011。
  • 合并哮喘者死亡风险更高:HR 3.76(95%CI 1.69–8.36),p=0.001。
  • 暴露组哮喘患病率显著更高(p=0.026),非哮喘肺部疾病患病率亦显著更高(p<0.001)。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,有芥子气暴露史的COVID-19感染者应被视为高危患者,医疗机构应准备提供重症监护,包括氧疗。
  • 有芥子气暴露史者更可能合并哮喘或其他肺部疾病,应加以关注。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: This study aims to assess the prognosis of inpatients with COVID-19 infection who have a history of sulfur mustard exposure.

METHODS: We started a cohort study in October 2020 and ended in May 2021 on inpatients with COVID-19 infection who had been admitted to university healthcare centers. The analytic sample included 960 inpatients having COVID-19 infection (192 with; and 768 without sulfur mustard exposure). The exposed patients were male war veterans, and the unexposed patients were male individually age-matched people. All patients had a positive RT-PCR test and a positive chest CT for COVID-19. The outcome was death within 28 days of admission, and the predictors were clinical features recorded at patients' bedsides.

RESULTS: There was a significantly higher prevalence for asthma (p = 0.026) and pulmonary disease other than asthma (p < 0.001) in patients with the exposure. Sulfur mustard exposure was associated with increased risk for mortality of COVID-19 [hazard ratio (95% CI) = 1.92 (1.14,3.24), p = 0.013]. Early intubation signified a poor prognosis [hazard = 7.34 (4.65,11.58), p < 0.001]. However, individuals with higher PaO2 [hazard = 0.97 (0.95,0.98), p < 0.001], or people undergoing O2 therapy early upon admission [hazard = 0.58 (0.38,0.89), p = 0.011] showed lower risks for mortality. Individuals with asthma were at higher risk for mortality [hazard = 3.76 (1.69,8.36), p = 0.001].

CONCLUSION: Individuals with COVID-19 infection and sulfur mustard exposure should be considered high-risk patients and that, healthcare settings should be ready to provide critical care for them, including O2 therapy. They are more likely to have asthma or other pulmonary diseases.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Kolivand P, Fathi M, Kheyrati L, et al. Exposure to sulfur mustard increases the risk for mortality in patients with COVID-19 infection: A cohort study. Am J Emerg Med. 2021. PMID: 34739867. doi:10.1016/j.ajem.2021.09.053

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。